Zee Wan Wong

1.4k total citations
21 papers, 433 citations indexed

About

Zee Wan Wong is a scholar working on Oncology, Public Health, Environmental and Occupational Health and General Health Professions. According to data from OpenAlex, Zee Wan Wong has authored 21 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Public Health, Environmental and Occupational Health and 4 papers in General Health Professions. Recurrent topics in Zee Wan Wong's work include COVID-19 and healthcare impacts (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Cancer therapeutics and mechanisms (3 papers). Zee Wan Wong is often cited by papers focused on COVID-19 and healthcare impacts (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Cancer therapeutics and mechanisms (3 papers). Zee Wan Wong collaborates with scholars based in Singapore, Australia and United States. Zee Wan Wong's co-authors include Peter Ang, Balram Chowbay, Suman Lal, Edwin Sandanaraj, Edmund J.D. Lee, Nan Soon Wong, London Lucien Ooi, Xiaoqiang Xiang, Srinivasa Rao Jada and William D. Figg and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The British Journal of Psychiatry.

In The Last Decade

Zee Wan Wong

18 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zee Wan Wong Singapore 10 251 138 79 65 63 21 433
Karen Lin United States 13 212 0.8× 49 0.4× 39 0.5× 42 0.6× 49 0.8× 22 612
Cheng‐Shyong Chang Taiwan 13 150 0.6× 137 1.0× 33 0.4× 18 0.3× 22 0.3× 44 554
SE Oliver United Kingdom 4 158 0.6× 69 0.5× 67 0.8× 22 0.3× 17 0.3× 6 382
Larry W. Buie United States 14 170 0.7× 91 0.7× 166 2.1× 27 0.4× 10 0.2× 38 535
Martin Paton United Kingdom 8 113 0.5× 370 2.7× 59 0.7× 24 0.4× 20 0.3× 19 597
Tusar Giri United States 16 55 0.2× 79 0.6× 25 0.3× 60 0.9× 47 0.7× 35 599
Ping Zheng China 8 138 0.5× 166 1.2× 37 0.5× 33 0.5× 7 0.1× 44 480
Randy V. Heysek United States 11 232 0.9× 88 0.6× 28 0.4× 34 0.5× 11 0.2× 20 569
Peter Fox Australia 9 219 0.9× 46 0.3× 98 1.2× 44 0.7× 6 0.1× 26 468

Countries citing papers authored by Zee Wan Wong

Since Specialization
Citations

This map shows the geographic impact of Zee Wan Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zee Wan Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zee Wan Wong more than expected).

Fields of papers citing papers by Zee Wan Wong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zee Wan Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zee Wan Wong. The network helps show where Zee Wan Wong may publish in the future.

Co-authorship network of co-authors of Zee Wan Wong

This figure shows the co-authorship network connecting the top 25 collaborators of Zee Wan Wong. A scholar is included among the top collaborators of Zee Wan Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zee Wan Wong. Zee Wan Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tsai, Daniel Hsiang‐Te, et al.. (2025). Antipsychotic therapy and suicide risk in patients with treatment-resistant depression: target trial emulation framework study. The British Journal of Psychiatry. 228(1). 37–45.
2.
Woollett, Anne, Mark Voskoboynik, Mark Shackleton, et al.. (2023). A capability framework to inform the fundamental requirements for clinical trial unit development, growth and long term success in outer metropolitan and rural areas. Contemporary Clinical Trials Communications. 32. 101072–101072. 1 indexed citations
3.
Burbury, Kate, Peter Brooks, Leslie Gilham, et al.. (2022). Telehealth in cancer care during the COVID-19 pandemic. Journal of Telemedicine and Telecare. 30(8). 1270–1284. 5 indexed citations
4.
Rasmussen, Bodil, Rachel J. Perry, Martha Hickey, et al.. (2022). Patient preferences using telehealth during the COVID‐19 pandemic in four Victorian tertiary hospital services. Internal Medicine Journal. 52(5). 763–769. 23 indexed citations
5.
6.
Passhak, Maria, Taehyun Kim, Ravit Geva, et al.. (2022). P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC). Annals of Oncology. 33. S277–S277. 3 indexed citations
7.
Delany, Clare, et al.. (2021). COVID-19 recovery: implications for cancer care clinicians. Supportive Care in Cancer. 30(2). 1003–1006. 3 indexed citations
8.
Wong, Zee Wan, et al.. (2021). Secondary exposure to organophosphate in the emergency department: analysis of an incident. Singapore Medical Journal. 66(12). 669–673.
9.
Wong, Zee Wan, et al.. (2020). Telehealth in cancer during COVID-19 pandemic. The Medical Journal of Australia. 1. 3 indexed citations
10.
Wong, Zee Wan, et al.. (2020). Telehealth in cancer care during the COVID‐19 pandemic. The Medical Journal of Australia. 213(5). 237–237. 23 indexed citations
11.
Underhill, Craig, Phillip Parente, Grant A. McArthur, et al.. (2020). Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID‐19 pandemic. Internal Medicine Journal. 50(10). 1282–1285. 9 indexed citations
12.
Lal, Sunil K., London Lucien Ooi, Zee Wan Wong, et al.. (2016). Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. The Pharmacogenomics Journal. 17(4). 337–343. 20 indexed citations
13.
14.
Saito, Tomoyuki, et al.. (2015). Review of Critical Incidents in a University Department of Anaesthesia. Anaesthesia and Intensive Care. 43(2). 238–243. 16 indexed citations
15.
Lal, Suman, Zee Wan Wong, Edwin Sandanaraj, et al.. (2008). Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Science. 99(4). 816–823. 113 indexed citations
16.
Sandanaraj, Edwin, Radojka M. Savić, Sean Lal, et al.. (2008). Population pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients. Journal of Clinical Oncology. 26(15_suppl). 13501–13501. 1 indexed citations
17.
Lal, Suman, Edwin Sandanaraj, Zee Wan Wong, et al.. (2008). CBR1andCBR3pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Science. 99(10). 2045–2054. 57 indexed citations
18.
Sandanaraj, Edwin, Suman Lal, Viknesvaran Selvarajan, et al.. (2008). PXR Pharmacogenetics: Association of Haplotypes with Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients. Clinical Cancer Research. 14(21). 7116–7126. 61 indexed citations
19.
Lal, Suman, Zee Wan Wong, Srinivasa Rao Jada, et al.. (2007). Novel SLC22A16 Polymorphisms and Influence on Doxorubicin Pharmacokinetics in Asian Breast Cancer Patients. Pharmacogenomics. 8(6). 567–575. 73 indexed citations
20.
Tan, York Kiat, et al.. (1999). Ethnicity, obstructive sleep apnoea and ischaemic heart disease.. PubMed. 28(2). 214–6. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Lin Breakdown of academic impact, for papers by Cheng‐Shyong Chang Breakdown of academic impact, for papers by SE Oliver Breakdown of academic impact, for papers by Larry W. Buie Breakdown of academic impact, for papers by Martin Paton Breakdown of academic impact, for papers by Tusar Giri Breakdown of academic impact, for papers by Ping Zheng Breakdown of academic impact, for papers by Randy V. Heysek Breakdown of academic impact, for papers by Peter Fox
Rankless by CCL
2026